跳至主要内容
临床试验/NCT00221871
NCT00221871Unknown不适用

Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).

University Health Network, Toronto1 个研究点 分布在 1 个国家开始时间: 2004年1月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
试验地点
1

研究概览

简要总结

Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Weight: 50-100 kg
  • •ASA: I, II, III
  • •Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

排除标准

  • •Contraindication to IVRA such as sickle cell disease.
  • •Any known hypersensitivity reaction to Ketamine.
  • •History of chronic pain or regular medication with analgesics.
  • •History of opioid dependence.
  • •Drug of alcohol abuse.
  • •Psychiatric disorder.
  • •Allergy to acetaminophen or codeine

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Proper Dosage of Ketamine in Intravenous Regional... | 临床试验